fasudil has been researched along with Hypertrophy, Right Ventricular in 14 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
Hypertrophy, Right Ventricular: Enlargement of the RIGHT VENTRICLE of the heart. This increase in ventricular mass is often attributed to PULMONARY HYPERTENSION and is a contributor to cardiovascular morbidity and mortality.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To investigate whether right ventricular hypertrophy in hypoxic pulmonary hypertension (HPH) rats could be prevented by treatment with Rho kinase inhibitor fasudil." | 7.81 | Effect of fasudil on hypoxic pulmonary hypertension and right ventricular hypertrophy in rats. ( Li, SY; Sun, XZ; Tian, XY; Wu, QQ, 2015) |
| "The fasudil treatment improved pulmonary hypertension, right ventricular hypertrophy, and pulmonary vascular lesions with suppression of VSMC proliferation and macrophage infiltration, enhanced VSMC apoptosis, and amelioration of endothelial dysfunction and VSMC hypercontraction." | 5.32 | Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. ( Abe, K; Hattori, T; Kaibuchi, K; Matsumoto, Y; Morikawa, K; Nakashima, Y; Oi, K; Shimokawa, H; Sueishi, K; Takeshit, A; Uwatoku, T, 2004) |
| "To investigate whether right ventricular hypertrophy in hypoxic pulmonary hypertension (HPH) rats could be prevented by treatment with Rho kinase inhibitor fasudil." | 3.81 | Effect of fasudil on hypoxic pulmonary hypertension and right ventricular hypertrophy in rats. ( Li, SY; Sun, XZ; Tian, XY; Wu, QQ, 2015) |
| "The effects of such regimens were investigated on hemodynamics, right ventricle hypertrophy, PDGF and ROCK in experimental monocrotaline (MCT)-induced pulmonary hypertension." | 3.80 | Concurrent rho-kinase and tyrosine kinase platelet-derived growth factor inhibition in experimental pulmonary hypertension. ( Jasińska-Stroschein, M; Orszulak-Michalak, D; Owczarek, J; Plichta, P, 2014) |
| " Overall, CAR-modified-liposomes of SOD plus fasudil, given every 72 h, was as efficacious as plain drugs, given every 48 h, suggesting that the formulation can reduce the total drug intake, systemic exposures, and dosing frequency." | 1.46 | Cocktail of Superoxide Dismutase and Fasudil Encapsulated in Targeted Liposomes Slows PAH Progression at a Reduced Dosing Frequency. ( Ahsan, F; Gupta, N; McMurtry, IF; Nozik-Grayck, E; Rashid, J; Stenmark, KR, 2017) |
| "Fasudil treatment lowered pulmonary artery systolic pressure, suppressed pulmonary artery smooth muscle cells proliferation, attenuated pulmonary artery medial wall thickening and inhibited right ventricular hypertrophy together with significant suppression of Rho kinase activity but not Rho activity." | 1.34 | Inhibition of rho kinase attenuates high flow induced pulmonary hypertension in rats. ( Li, AW; Li, FH; Sun, RP; Xia, W; Zhao, CF, 2007) |
| "The fasudil treatment improved pulmonary hypertension, right ventricular hypertrophy, and pulmonary vascular lesions with suppression of VSMC proliferation and macrophage infiltration, enhanced VSMC apoptosis, and amelioration of endothelial dysfunction and VSMC hypercontraction." | 1.32 | Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. ( Abe, K; Hattori, T; Kaibuchi, K; Matsumoto, Y; Morikawa, K; Nakashima, Y; Oi, K; Shimokawa, H; Sueishi, K; Takeshit, A; Uwatoku, T, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (35.71) | 29.6817 |
| 2010's | 9 (64.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jasińska-Stroschein, M | 1 |
| Owczarek, J | 1 |
| Plichta, P | 1 |
| Orszulak-Michalak, D | 1 |
| Gosal, K | 1 |
| Dunlop, K | 1 |
| Dhaliwal, R | 1 |
| Ivanovska, J | 3 |
| Kantores, C | 3 |
| Desjardins, JF | 1 |
| Connelly, KA | 1 |
| McNamara, PJ | 3 |
| Jain, A | 1 |
| Jankov, RP | 3 |
| Sun, XZ | 1 |
| Li, SY | 1 |
| Tian, XY | 1 |
| Wu, QQ | 1 |
| Zychowski, KE | 1 |
| Lucas, SN | 1 |
| Sanchez, B | 1 |
| Herbert, G | 1 |
| Campen, MJ | 1 |
| Gupta, N | 1 |
| Rashid, J | 1 |
| Nozik-Grayck, E | 1 |
| McMurtry, IF | 2 |
| Stenmark, KR | 1 |
| Ahsan, F | 1 |
| Ziino, AJ | 1 |
| Belcastro, R | 1 |
| Xu, EZ | 2 |
| Lau, M | 1 |
| Tanswell, AK | 1 |
| Mouchaers, KT | 1 |
| Schalij, I | 1 |
| de Boer, MA | 1 |
| Postmus, PE | 1 |
| van Hinsbergh, VW | 1 |
| van Nieuw Amerongen, GP | 1 |
| Vonk Noordegraaf, A | 1 |
| van der Laarse, WJ | 1 |
| Engelberts, D | 1 |
| Kavanagh, BP | 1 |
| Yasuda, T | 1 |
| Tada, Y | 1 |
| Tanabe, N | 1 |
| Tatsumi, K | 1 |
| West, J | 1 |
| Abe, K | 2 |
| Shimokawa, H | 3 |
| Morikawa, K | 1 |
| Uwatoku, T | 2 |
| Oi, K | 2 |
| Matsumoto, Y | 1 |
| Hattori, T | 1 |
| Nakashima, Y | 1 |
| Kaibuchi, K | 2 |
| Sueishi, K | 1 |
| Takeshit, A | 1 |
| Nagaoka, T | 1 |
| Gebb, SA | 1 |
| Karoor, V | 1 |
| Homma, N | 1 |
| Morris, KG | 1 |
| Oka, M | 1 |
| Tawara, S | 2 |
| Hizume, T | 1 |
| Fukumoto, Y | 2 |
| Li, FH | 1 |
| Xia, W | 1 |
| Li, AW | 1 |
| Zhao, CF | 1 |
| Sun, RP | 1 |
14 other studies available for fasudil and Hypertrophy, Right Ventricular
| Article | Year |
|---|---|
Concurrent rho-kinase and tyrosine kinase platelet-derived growth factor inhibition in experimental pulmonary hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Becaplermin; Benzamides; Disease Models, Ani | 2014 |
Rho kinase mediates right ventricular systolic dysfunction in rats with chronic neonatal pulmonary hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cyclic Nucleotide Phosphodiesterases, Type 5 | 2015 |
Effect of fasudil on hypoxic pulmonary hypertension and right ventricular hypertrophy in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Heart; Hypertension, | 2015 |
Hypoxia-induced pulmonary arterial hypertension augments lung injury and airway reactivity caused by ozone exposure.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Air Pollutants; Animals; Bronchial Hyperreactivity; B | 2016 |
Cocktail of Superoxide Dismutase and Fasudil Encapsulated in Targeted Liposomes Slows PAH Progression at a Reduced Dosing Frequency.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Arterial Pressure; Chemistry, Pharmaceutical | 2017 |
Effects of rho-kinase inhibition on pulmonary hypertension, lung growth, and structure in neonatal rats chronically exposed to hypoxia.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Airway Remodeling; Amides; Animals; Animals, Newborn; | 2010 |
Fasudil reduces monocrotaline-induced pulmonary arterial hypertension: comparison with bosentan and sildenafil.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Oral; Animals; Antihypertensive Agent | 2010 |
Rescue treatment with a Rho-kinase inhibitor normalizes right ventricular function and reverses remodeling in juvenile rats with chronic pulmonary hypertension.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Age Factors; Aging; Amides; Animals; Apoptosis; Cell | 2010 |
Rho-kinase inhibition alleviates pulmonary hypertension in transgenic mice expressing a dominant-negative type II bone morphogenetic protein receptor gene.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Acute-Phase Proteins; Animals; Blotting, Western; Bon | 2011 |
Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Dose-Response Relationship, Drug; Endotheliu | 2004 |
Involvement of RhoA/Rho kinase signaling in pulmonary hypertension of the fawn-hooded rat.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Altitude; Animals; Blood Pressure; Blotting, Western; | 2006 |
Long-term inhibition of Rho-kinase ameliorates hypoxia-induced pulmonary hypertension in mice.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Arterioles; Blotting, Western; Disease Model | 2006 |
Inhibition of rho kinase attenuates high flow induced pulmonary hypertension in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cell Proliferation; Enzyme Activation; Hyper | 2007 |
Effects of combined therapy with a Rho-kinase inhibitor and prostacyclin on monocrotaline-induced pulmonary hypertension in rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Disease Models, Animal; Drug Interactions; D | 2007 |